Test Price
2,800 AEDโ Home Collection Available
LOXL1 Gene Exfoliation Syndrome Susceptibility DNA Test | UAE | 2800 AED
Executive Summary & Core Metrics
DNA Labs UAE offers a state-of-the-art genetic DNA test for LOXL1 gene variants associated with pseudoexfoliation syndrome. Performed via Next-Generation Sequencing (NGS) with 99.9% diagnostic sensitivity in our ISO 9001:2015 accredited laboratory, this test enables early risk stratification for secondary open-angle glaucoma. Premium logistics include temperature-controlled cold-chain home collection and VIP mobile phlebotomy, available daily from 8 AM to 11 PM. Post-test telephonic clinical guidance is provided for result interpretation. Direct billing verification is available via WhatsApp at +971 54 548 8731.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: Temperature-Controlled Cold-Chain Home Collection and VIP Mobile Phlebotomy (daily 8 AM โ 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The LOXL1 gene susceptibility test identifies germline variants in the LOXL1 gene that confer increased risk for pseudoexfoliation syndrome, a leading cause of secondary open-angle glaucoma. This NGS-based assay comprehensively sequences the LOXL1 coding regions and flanking intronic regions, delivering results with 99.9% analytical sensitivity in 3โ4 weeks. Early detection allows for preventive surveillance, annual comprehensive eye exams, and intraocular pressure monitoring to preserve vision.
| Feature | Our LOXL1 NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | Full gene coverage, 99.9% sensitivity | Targeted exons only, lower variant detection |
| Method | Next-Generation Sequencing (NGS) | Capillary electrophoresis (Sanger) |
| Turnaround Time | 3โ4 Weeks | 5โ6 Weeks |
Physician Insight & Safety Protocols
โGenetic testing for LOXL1 variants is a powerful tool for early risk stratification in pseudoexfoliation syndrome, but it must always be interpreted within a comprehensive clinical context including full ocular examination, intraocular pressure monitoring, and family history analysis. A positive result indicates susceptibility, not disease inevitability, and should guide enhanced surveillance such as annual dilated eye exams and pressure checks. Patients are encouraged to discuss results with their ophthalmologist and genetic counsellor for personalised management.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication Safety & Clinical Oversight
โ ๏ธ Do not stop prescribed medications without physician approval.
Altering or discontinuing glaucoma medications or systemic treatments can lead to irreversible vision loss or uncontrolled intraocular pressure. Always consult your ophthalmologist before making any changes.
Exclusion Criteria & Emergency Red Flags
Safety Exclusion Criteria:
- This genetic test is contraindicated in individuals with acute ocular trauma, active intraocular infection, or hemodynamic instability. It is not intended for standalone diagnosis of pseudoexfoliation glaucoma; clinical correlation is mandatory.
Emergency Red Flags โ Seek Immediate Ophthalmic Care:
- Sudden vision loss, severe eye pain, halos around lights, nausea/vomiting โ these may indicate acute angle-closure glaucoma and require emergency treatment regardless of genetic results.
Patient FAQ & Clinical Guidance
1. What is the clinical purpose of the LOXL1 gene susceptibility test?
Direct Answer: This test detects germline variants in the LOXL1 gene to estimate an individualโs lifelong risk of developing pseudoexfoliation syndrome and subsequent secondary open-angle glaucoma. Positive results prompt enhanced ophthalmic surveillance and preventive care before symptoms arise.
2. How is the sample collected and what preparation is required?
Direct Answer: A simple peripheral blood draw (whole blood, DNA FTA card, or extracted DNA) is performed by our VIP mobile phlebotomist during a home collection visit. Fasting is not required. A pre-test genetic counselling session is recommended to document family pedigree and discuss implications.
3. How are the results interpreted and what actions follow?
Direct Answer: Variants are classified using ACMG guidelines by a board-certified molecular geneticist. A positive result leads to personalised surveillance including annual comprehensive eye exams, intraocular pressure checks, and gonioscopy. A negative result does not eliminate the need for routine screening based on age and other risk factors.
4. Is genetic counselling included in the test?
Direct Answer: Yes, post-test telephonic clinical guidance is provided to explain results, risk implications, and recommended follow-up. Pre-test counselling is available upon request to discuss testing benefits, limitations, and familial implications.
5. What is the turnaround time and how can I receive results?
Direct Answer: The typical turnaround time is 3โ4 weeks from sample receipt. Results are delivered via secure digital report emailed to you and your referring physician, with a telephonic consultation to discuss key findings.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
This service complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data is encrypted, stored securely, and accessed only by authorised personnel. ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139). DHA Facility License: 1143.
Clinical & Logistical Metadata
| Test Name | LOXL1 Gene Exfoliation Syndrome Susceptibility DNA Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Whole Blood (Peripheral) โ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | Z13.5 (Encounter for screening for eye disorders) |
| LOINC Code | 94400-6 (LOXL1 gene mutation analysis) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians